Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (371-380 of 759) with videos related to

Pageof 76
Sort By:
Journal of the National Cancer Institute|April 5, 2014
Multiple myeloma in the very old: an IASIA conference reportSascha A Tuchman, Gary R Shapiro, William B Ershler, et al.
Blood|October 19, 2007
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaAngela Dispenzieri, Robert A Kyle, Jerry A Katzmann, et al.
Journal of Magnetic Resonance Imaging : JMRI|February 26, 2017
Cardiac MR elastography for quantitative assessment of elevated myocardial stiffness in cardiac amyloidosisArvin Arani, Shivaram P Arunachalam, Ian C Y Chang, et al.
Bone Marrow Transplantation|November 19, 2020
Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosisIuliana Vaxman, M Hasib Sidiqi, Abdullah S Al Saleh, et al.
Leukemia|June 25, 2021
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosisAngela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, et al.
Human Pathology|October 16, 2025
Dual amyloidosis: A clinicopathologic and proteomic analysis of 111 patientsJoanna C Dalland, Surendra Dasari, Jason D Theis, et al.
Blood Cancer Journal|May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
ESC Heart Failure|August 31, 2024
Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosisJennifer M Amadio, Martha Grogan, Eli Muchtar, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
British Journal of Haematology|May 26, 2012
Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myelomaAlexandra J Greenberg, S Vincent Rajkumar, Dirk R Larson, et al.
Pageof 76

Showing results (371-380 of 759) with videos related to

Sort By:
Pageof 76
Journal of the National Cancer Institute|April 5, 2014
Multiple myeloma in the very old: an IASIA conference reportSascha A Tuchman, Gary R Shapiro, William B Ershler, et al.
Blood|October 19, 2007
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaAngela Dispenzieri, Robert A Kyle, Jerry A Katzmann, et al.
Journal of Magnetic Resonance Imaging : JMRI|February 26, 2017
Cardiac MR elastography for quantitative assessment of elevated myocardial stiffness in cardiac amyloidosisArvin Arani, Shivaram P Arunachalam, Ian C Y Chang, et al.
Bone Marrow Transplantation|November 19, 2020
Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosisIuliana Vaxman, M Hasib Sidiqi, Abdullah S Al Saleh, et al.
Leukemia|June 25, 2021
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosisAngela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, et al.
Human Pathology|October 16, 2025
Dual amyloidosis: A clinicopathologic and proteomic analysis of 111 patientsJoanna C Dalland, Surendra Dasari, Jason D Theis, et al.
Blood Cancer Journal|May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
ESC Heart Failure|August 31, 2024
Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosisJennifer M Amadio, Martha Grogan, Eli Muchtar, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
British Journal of Haematology|May 26, 2012
Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myelomaAlexandra J Greenberg, S Vincent Rajkumar, Dirk R Larson, et al.
Pageof 76